IMR Press / EJGO / Volume 33 / Issue 1 / pii/1631086201828-972818639

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinumrefractory/resistant epithelial ovarian cancer
Show Less
1 Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo (Japan)
Eur. J. Gynaecol. Oncol. 2012, 33(1), 86–89;
Published: 10 February 2012
Abstract

Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m2) was administered intravenously on days 1, 8 and 15 every four weeks. PLD (50 mg/m2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p <0.05), respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p= 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-11 group (p <0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.
Keywords
Ovarian cancer
Recurrence
Platinum-resistant
Irinotecan
Liposomal doxorubicin
Share
Back to top